Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:J05AX17
|
| gptkbp:brand |
gptkb:Prevymis
|
| gptkbp:CASNumber |
917389-32-3
|
| gptkbp:discoveredBy |
gptkb:Merck_&_Co.
|
| gptkbp:drugClass |
antiviral
|
| gptkbp:hasMolecularFormula |
C29H28F4N4O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
Letermovir
|
| gptkbp:indication |
CMV-seropositive adult recipients of an allogeneic hematopoietic stem cell transplant
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits CMV DNA terminase complex
|
| gptkbp:proteinBinding |
98%
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
vomiting diarrhea peripheral edema |
| gptkbp:usedFor |
prevention of cytomegalovirus (CMV) infection
|
| gptkbp:bfsParent |
gptkb:79617-96-2
|
| gptkbp:bfsLayer |
6
|